scholarly journals Significance of confirming Epstein-Barr virus nuclear antibody as tumor marker

2007 ◽  
Vol 64 (7) ◽  
pp. 459-462 ◽  
Author(s):  
Svetlana Stosic-Divjak ◽  
Vojko Djukic ◽  
Ivan Boricic ◽  
Alek Racic ◽  
Isidora Divjak ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Blood Donors ◽  
Malignant Tumors ◽  
Barr Virus ◽  
Group A ◽  
Causal Treatment ◽  
Nasopharyngeal Tumors ◽  
Epstein Barr ◽  
Group B ◽  
Group D

Backgrounnd/Aim. Study of the association between Epstein-Barr virus (EBV) and the tumors of the nasopharynx renders an opportunity to introduce causal treatment. Already have been proven the anti-EBV (anti-Epstein-Barr nucleus antigene) antibodies in the blood serum of the patients infected with EBV, while over 91% of the patients with nasopharyngeal malignant tumors also have a detectable anti-EBV marker. The aim of this research was to determine if there were anti-EBV antibodies in the serum of the patients with the already verified nasopharyngeal malignant tumors, and, if there were, to determine the quantitative ratio to the values in the serum of the healthy controls. Methods. The study involved 74 individuals in the period from 1994?2001 divided into four groups: group A counting 11 patients with undifferentiated carcinome of nasopharyngeal type (UCNT); group B counting 25 patients with UCNT Xray treated at least three years before the onset of the study; group C including 28 healthy subjecets (blood donors), and the group D with 10 patients with planocellular nasopharyngeal carcinoma. Serologic diagnostics of the patients serum was performed using the techniques of Reedman and Klein for the detection of anti-EBV antibodies in the serum. Results. The presence of the statistically significantly higher values of the mean geometric titer (MGT) of the anti- EBNA antibodies was determined in 36 patients with histologically verified UCNT as compared with the control groups including 10 patients with planocellular carcinomas of the nasopharynx and 28 blood donors. Presented were anti-EBNA titers with 95% confidence interval for any participants according to the Hoo clinical classification of nasopharyngeal tumors, as well as according to the fact if they had been radiotreated within the previous three years. Conclusion. The results of this study confirm the conclusions of the recent literature on the possible etiopathogenesis of nasopharyngeal tumors and the use of viral anti-EBNA antibodies as viral markers in the diagnostics of UCNT diseases. .

Use of Plasma Epstein-Barr virus DNA Monitoring as a Tumor Marker in follow-up of Patients with Nasopharyngeal Carcinoma: Preliminary Results and Report of two Cases

2007 ◽  
Vol 22 (3) ◽  
pp. 194-199 ◽  
Author(s):  
E. Özyar ◽  
M. Gültekin ◽  
A. Alp ◽  
G. Hasçelik ◽  
Ö. Ugur ◽  
...  
Keyword(s):  
Quantitative Analysis ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Nasopharyngeal Cancer ◽  
Barr Virus ◽  
Group A ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Group B

Recent studies suggest that plasma Epstein-Barr virus (EBV) DNA may reflect tumor burden in patients with nasopharyngeal cancer. A prospective study was initiated to investigate this correlation in 125 patients (34 pretreatment [Group A], 78 in remission [Group B] and 13 relapsed [Group C]) and 19 healthy controls. In group A, EBV DNA was detected in plasma samples of 24 (70%) patients. In Group B, EBV DNA was detected in 7 patients (range 77–13,731 copies/mL) and further imaging in all but one of these patients revealed active disease confirmed by ultrasound-guided fine-needle biopsy. There was only one false-positive case; this patient is currently under follow-up. Here we describe 2 of the 7 patients with detectable plasma EBV DNA in whom recurrence was documented by PET scan during follow-up. Our results showed that in group B the positive predictive value of quantitative analysis of plasma EBV DNA was 85%. Quantitative analysis of EBV DNA in plasma seems to become an integral part of screening, staging, monitoring, and prediction of relapse in patients with nasopharyngeal carcinoma. However, previous studies cannot be considered definitive and more reports on the use of this technique are urgently needed from both endemic and non-endemic regions.

scholarly journals One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody

Blood ◽  
1993 ◽  
Vol 82 (8) ◽  
pp. 2485-2493 ◽  
Author(s):  
U Galili ◽  
F Anaraki ◽  
A Thall ◽  
C Hill-Black ◽  
M Radic
Keyword(s):  
B Lymphocytes ◽  
Blood Group ◽  
Enzyme Linked Immunosorbent Assay ◽  
Barr Virus ◽  
Effective System ◽  
Group A ◽  
Igh Gene Rearrangement ◽  
Epstein Barr ◽  
B Lymphoid ◽  
Group B

The natural anti-Gal antibody constitutes 1% of circulating IgG in humans and interacts specifically with the carbohydrate epitope Gal alpha 1–3Gal beta 1–4GlcNAc-R (the alpha-galactosyl epitope). In view of the unusually large amounts of this antibody in the serum, it was of interest to determine the proportion of circulating B lymphocytes capable of synthesizing anti-Gal. For this purpose, blood B lymphocytes were incubated with Epstein-Barr virus (EBV) and plated in microtiter wells. Proliferation of the EBV transformed B lymphocytes was readily visible after 3 weeks of incubation. The supernatants from wells containing proliferating B-lymphoid clones were assayed for anti-Gal by an agglutination assay with rabbit red blood cells and the specificity of the agglutinating antibodies was further confirmed by their interaction with synthetic oligosaccharides and by enzyme-linked immunosorbent assay with glycoproteins. Approximately 5% of the wells contained anti-Gal antibodies. Limiting dilution studies and IgH gene rearrangement patterns suggested that each well contained an average of five proliferating B-lymphoid clones. Thus, it is concluded that approximately 1% of circulating B lymphocytes are capable of producing anti-Gal. The proportion of anti-Gal--producing lymphoid clones exceeds by fourfold that of clones producing anti-blood group A or anti-blood group B antibodies. Individual anti-Gal clones display fine variations in their combining site, as indicated by their differential interaction with alpha-galactosyl epitopes on glycolipids and on N-linked carbohydrate chains of glycoproteins. The high frequency of precursor B lymphocytes capable of producing anti-Gal, found in every individual and the restricted specificity of this antibody to alpha-galactosyl epitopes, potentially makes anti-Gal--producing lymphocytes an effective system for studying human Ig genes involved in the natural immune response to structurally defined haptens.

scholarly journals Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx

Blood ◽  
1996 ◽  
Vol 87 (2) ◽  
pp. 812-817 ◽  
Author(s):  
C Alfieri ◽  
J Tanner ◽  
L Carpentier ◽  
C Perpete ◽  
A Savoie ◽  
...  
Keyword(s):  
Cord Blood ◽  
Blood Donor ◽  
Epstein Barr Virus ◽  
Blood Donors ◽  
Barr Virus ◽  
Ebv Infection ◽  
Transplant Patients ◽  
Throat Wash ◽  
Transforming Activity ◽  
Epstein Barr

A previous study (Savoie et al, Blood 83:2715, 1994) identified eight transplant patients who acquired Epstein-Barr virus (EBV) infection during the peritransplant period. Three of these patients subsequently developed B-cell lymphoproliferative disease within 4 months of transplantation. Among these, there was a 16-year-old liver transplant patient who was negative for EBV at the time of transplant and who received an EBV-negative organ. After transplant, this patient was transfused with 9 U of packed red blood cells. Eight of the donors were EBV-positive and one was EBV-negative. We succeeded in obtaining spontaneous lymphoblastoid cell lines (LCLs) from the blood of three of these donors, one of whom also yielded a cord-blood line established with his throat-wash EBV. Blood from a fourth donor did not yield an LCL, but his throat washing did have transforming activity when inoculated onto cord-blood leukocytes. We initially could establish spontaneous LCLs only from the recipient's blood. However, a throat- wash sample taken 11 weeks later did show transforming activity. The recipient was shown to have acquired the EBV infection from one of eight EBV-seropositive blood donors. Analysis of fragment length polymorphisms after polymerase chain reaction amplification of the EBV BamHI-K fragment was used to establish strain identity. Western blot analysis for existence of size polymorphisms in three classes of Epstein-Barr nuclear antigens (EBNA-1, EBNA-2, and EBNA-3) confirmed the DNA results. It is noteworthy that the blood donor responsible for transmitting his EBV strain to the recipient had experienced clinical infectious mononucleosis 15 months before donating blood. Our results may, thus, indicate a requirement for leukodepletion of blood destined for immunosuppressed EBV-negative patients. Finally, blood donors with a recent history of infectious mononucleosis should probably be identified so that their blood is not given to EBV-negative transplant patients.

scholarly journals Molecular diagnosis of cytomegalovirus, Epstein-Barr virus and Herpes virus 6 among blood donors in Ouagadougou, Burkina Faso

2014 ◽  
Vol 14 (S2) ◽  
Author(s):  
Lassina Traore ◽  
Issoufou Tao ◽  
Cyrille Bisseye ◽  
Florencia Djigma ◽  
Djénéba Ouermi ◽  
...  
Keyword(s):  
Burkina Faso ◽  
Molecular Diagnosis ◽  
Epstein Barr Virus ◽  
Herpes Virus ◽  
Blood Donors ◽  
Barr Virus ◽  
Epstein Barr ◽  
Herpès Virus

Kawasaki syndrome associated with group A streptococcal and Epstein-Barr virus co-infections

2002 ◽  
Vol 22 (3) ◽  
pp. 257-260 ◽  
Author(s):  
Michelle Barton ◽  
Roxanne Melbourne ◽  
Priscilla Morais ◽  
Celia Christie
Keyword(s):  
Epstein Barr Virus ◽  
Kawasaki Syndrome ◽  
Barr Virus ◽  
Group A ◽  
Epstein Barr

scholarly journals Burkitt Lymphoma with Multiorgan Involvement

2018 ◽  
Vol 04 (01) ◽  
pp. 024-028
Author(s):  
Venus Kumar ◽  
H R Chandrashekhar ◽  
Suresh Hanagavadi
Keyword(s):  
B Lymphocytes ◽  
Burkitt Lymphoma ◽  
Epstein Barr Virus ◽  
Malignant Tumors ◽  
Indian Children ◽  
Barr Virus ◽  
Poorly Differentiated ◽  
Epstein Barr ◽  
Rare Malignancy ◽  
Solid Malignant Tumors

AbstractBurkitt lymphoma (BL) is classified as a poorly differentiated lymphocytic lymphoma of B lymphocytes. It mainly affects children. It is one of the rapidly growing tumors in humans, with profuse proliferation. It is a rare malignancy comprised of only 0.76% of solid malignant tumors among Indian children.Symptoms occur because of rapid turnover of the mature B lymphocytes with involvement of the extranodal sites and involvement of adjacent organs. Initially, this tumor was identified in Africans. The cause of this tumor is uncertain, but shows strong evidence with Epstein–Barr virus (EBV) in its development. A case of BL with multiorgan involvement in a 7-year-old girl was reported, which was confirmed by immunohistochemistry (IHC).

scholarly journals Oropharyngeal Group A Streptococcal Colonization Disrupts Latent Epstein-Barr Virus Infection

2013 ◽  
Vol 209 (2) ◽  
pp. 255-264 ◽  
Author(s):  
Seigo Ueda ◽  
Satoshi Uchiyama ◽  
Tarik Azzi ◽  
Claudine Gysin ◽  
Christoph Berger ◽  
...  
Keyword(s):  
Virus Infection ◽  
Epstein Barr Virus ◽  
Epstein Barr Virus Infection ◽  
Barr Virus ◽  
Group A ◽  
Epstein Barr ◽  
Barr Virus Infection
Sign in / Sign up

Export Citation Format

Share Document